Industry News
Vale Jamie Callachor
The NSW biotech community has been saddened by the loss of Jamie Callachor, who passed away on November 2. [ + ]
Sunshine Heart gets thumbs-up for Australian pilot study
Sunshine Heart (ASX:SHC) has received ethics committee approval to conduct implantations of its C-Pulse device in Australia at Southern Health Monash Medical Centre in Melbourne. [ + ]
Rockeby shares soar after bird flu test deal
Shares in Rockeby Biomed (ASX:RBY) quadrupled in value today after the company announced it has signed a deal with Thailand-based Pacific Biotech for the exclusive marketing and distribution rights in Europe, the Asia-Pacific and South Africa to two tests for avian flu. [ + ]
Epitan receives marketing approval for Zindaclin
Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has received approval from the Therapeutic Goods Administration (TGA) for the registration of anti-acne treatment Zindaclin. [ + ]
Qld to join synchrotron
The Queensland government and a consortium of Queensland universities will together invest AUD$5 million in the Melbourne-based Australian Synchrotron. [ + ]
BresaGen to make Psiron melanoma therapy
Sydney biotech Psiron (ASX:PSX) will be the first client for rejuvenated Adelaide biotechnology manufacturer BresaGen's new pilot production plant for therapeutics produced in mammalian cell cultures. [ + ]
Acrux terminates Napa licence
Acrux DDS, a wholly owned subsidiary of Melbourne-based Acrux (ASX:ACR), has terminated an exclusive licence agreement it signed in May 2005 with US firm Napa Biosciences. [ + ]
CyGenics acquires 51 per cent of BioCell
Cell therapy company CyGenics (ASX:CYN) has taken a 51 per cent controlling equity interest in cord blood stem cell banking business BioCell. [ + ]
Cytopia picks up $3m grant
Melbourne oncology drug developer Cytopia (ASX:CYT) has been offered a AUD$3 million federal government Commercial Ready grant to expand clinical development of its lead anti-cancer drug CYT997. [ + ]
Method to detect potential bioterrorism agent
A new combination of analytical chemistry and mathematical data analysis techniques allows the rapid identification of the species, strain and infectious phase of the potential biological terrorism agent Coxiella burnetii. The bacterium causes the human disease Q fever, which can cause serious illness and even death.
[ + ]CRO Datapharm to team with e-diary firm
Australian contract research organisation Datapharm has entered into a strategic alliance with Brussels and Cambridge based Symfo, a specialist in electronic diary solutions for patients. [ + ]
Prana pleased with Alzheimer's trial results
Prana Biotech (ASX:PBT, NASDAQ:PRAN) announced today that its candidate PBT2 therapy for Alzheimer's disease has come through a phase I single-dose escalation trial in the Netherlands, with a superior pharmacokinetic profile to its predecessor, clioquinol. [ + ]
Phosphagenics signs development agreement with US firm ALZA
Melbourne's Phosphagenics (ASX:POH) has entered into an agreement with US-based ALZA Corp to determine the feasibility of delivering a number of compounds nominated by ALZA using Phosphagenics' patented transdermal delivery system, TPM-01. [ + ]
Peptech to step up R&D after profit boost
Sydney-based Peptech (ASX:PTD) expects to boost its R&D spend in the next year, in the wake of a net profit of AUD$25.7 million for the year ended September 30. [ + ]
Novogen says remuneration vote subject to proxy error
Novogen (ASX:NRT) has cited a "voting systems error" as the reason why a significant number of proxy votes were cast against the resolution to adopt the company's remuneration report for the year ended June 30 at its AGM in late October. [ + ]
